Company

Vivacta Biotechnology

Vivacta Biotechnology conducts research and development in cell and gene technologies.

About

Vivacta Biotechnology conducts biotechnology and medical research, including work on human stem cell and gene technologies. Its activities include technical services, technology consulting, and international trade. Founded in 2025 and based in Shanghai, China, it raised USD 50 million in Series A funding in April 2026, co-led by Loyal Valley Capital and Decheng Capital, with participation from OrbiMed Advisors, Hankang Capital, Xiamen C&D Emerging Industry Equity Investment, Eisai Innovation, Qiming Venture Partners, Shunxi Fund, and Apricot Capital.

3Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in